Kaplan-Meier analysis of The Cancer Genome Atlas (TCGA) GBM cohort demonstrated a trend toward reduced overall survival in patients with high CDK12 expression (median 11.2 months) compared with those with low expression (median 17.9 months). The gene discussed is CDK12; the disease is glioblastoma.